$2975 | SAVE $525 | Single User
$5950 | SAVE $1,050 | Site License
$8925 | SAVE $1,575 | Enterprise License

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2018

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2018
[Lowest Price Guaranteed: $2,975]

Published by Global Markets Direct: 14 Aug 2018 | 218016 | In Stock
Related Topics: Bladder Cancer , Breast Cancer , Cancer , Colorectal Cancer , Gas , Lung Cancer , Ovarian Cancer , Pancreatic Cancer

Introduction

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2018

Summary

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2018, outlays comprehensive information on the Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e is a human gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. It promotes tumor development through its role as a cell adhesion molecule. It regulates differentiation, apoptosis, and cell polarity.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 1 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Gastrointestinal which include indications Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma, Colorectal Cancer, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pancreatic Cancer, Peritoneal Tumor, Recurrent Glioblastoma Multiforme (GBM), Solid Tumor and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

- The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and enlists all their major and minor projects

- The report assesses Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2018

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Overview

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Companies Involved in Therapeutics Development

    Akshaya Bio Inc

    Bavarian Nordic A/S

    Etubics Corp

    OSE Immunotherapeutics

    Vaxon Biotech

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Drug Profiles

    CV-301 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    DK-001 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ETBX-011 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GI-6207 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    OSE-2101 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Synthetic Peptides to Activate CEACAM5 for Crohn's Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine to Target CEA for Colorectal Cancer - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine to Target CEA for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vbx-016 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vbx-026 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Dormant Products

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Discontinued Products

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Product Development Milestones

    Featured News & Press Releases

    Jul 11, 2018: Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

    Jul 05, 2018: OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi

    Jul 02, 2018: OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi

    Jun 19, 2018: Exploring a New Treatment for Metastatic Colorectal Cancer

    Mar 15, 2018: OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

    Mar 08, 2018: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer

    Feb 27, 2018: OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

    Jan 25, 2018: OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi in Immuno-Oncology Applications

    Dec 07, 2017: OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

    Jun 23, 2017: OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi in Advanced Lung Cancer

    Mar 21, 2017: Direct Tumor Vaccination Shown to Induce Anti-tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer

    Mar 10, 2017: Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer

    Jan 24, 2017: OSE Immunotherapeutics Announces That the Independent Data Monitoring Committee Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi in Non-Small Cell Lung Cancer

    Jan 04, 2017: Bristol-Myers, Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer

    Dec 29, 2016: Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

218016 | GMDHC1620TDB

Number of Pages

59

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2018
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconi...
20 Feb 2018 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Global and Chinese Carcinoembryonic Antigen Industry, 2017 Market Research Report
The 'Global and Chinese Carcinoembryonic Antigen Industry, 2012-2022 Market Research Report' is a pr...
29 Dec 2017 by Prof Research USD $2,550 (normally
USD $3,000)
More Info
SAVE 15% today! Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
09 Dec 2017 by Venture Planning Group (VPG) USD $3,698 (normally
USD $4,351)
More Info
SAVE 15% today! Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2017
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconi...
29 Aug 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
30 Mar 2017 by Venture Planning Group (VPG) USD $3,698 (normally
USD $4,351)
More Info
SAVE 15% today! Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
09 Dec 2016 by Venture Planning Group (VPG) USD $2,380 (normally
USD $2,800)
More Info
SAVE 15% today! Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
09 Dec 2016 by Venture Planning Group (VPG) USD $3,698 (normally
USD $4,351)
More Info
SAVE 15% today! Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2016
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconi...
09 Nov 2016 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Carcinoembryonic Antigen (CEA): US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
24 Jun 2016 by Venture Planning Group (VPG) USD $3,698 (normally
USD $4,351)
More Info
SAVE 15% today! Carcinoembryonic Antigen (CEA): US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
24 Jun 2016 by Venture Planning Group (VPG) USD $3,698 (normally
USD $4,351)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2018 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...